| scholarly article | Q13442814 |
| P2093 | author name string | Helena Cortez-Pinto | |
| Mariana Verdelho Machado | |||
| P2860 | cites work | Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities | Q24303914 |
| Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis | Q24319960 | ||
| Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis | Q24625697 | ||
| The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis | Q25257576 | ||
| Diagnosis and management of non‐alcoholic fatty liver disease and related metabolic disorders: Consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology (非酒精性脂肪性肝病与相关代谢紊乱诊疗共识——中华医学会内分泌学分会肝病与代谢学组) | Q26998471 | ||
| What Should We Recommend to Our Patients with NAFLD Regarding Alcohol Use? | Q27011312 | ||
| Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease | Q27496667 | ||
| Liver fibrosis in overweight patients | Q28145482 | ||
| One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study | Q28246121 | ||
| Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis | Q28251261 | ||
| Alcohol consumption and mortality among middle-aged and elderly U.S. adults | Q28256034 | ||
| The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology | Q28267844 | ||
| Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality | Q28292632 | ||
| Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity | Q28297290 | ||
| The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis | Q28345942 | ||
| Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity | Q28512778 | ||
| Increased oxidative stress in obesity and its impact on metabolic syndrome | Q29012150 | ||
| Adopting Moderate Alcohol Consumption in Middle Age: Subsequent Cardiovascular Events | Q29012353 | ||
| Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease | Q29417076 | ||
| Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese | Q29417094 | ||
| Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease | Q29614897 | ||
| Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults | Q29614911 | ||
| Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity | Q29614914 | ||
| Design and validation of a histological scoring system for nonalcoholic fatty liver disease | Q29614930 | ||
| Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity | Q29614932 | ||
| Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study | Q29615122 | ||
| Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition | Q29615691 | ||
| The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance | Q29616026 | ||
| The natural history of nonalcoholic fatty liver disease: a population-based cohort study | Q29617161 | ||
| Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease | Q29619334 | ||
| Immunological and inflammatory functions of the interleukin-1 family | Q29619669 | ||
| Long-term follow-up of patients with NAFLD and elevated liver enzymes | Q29620024 | ||
| Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) | Q29620308 | ||
| Protective and pathogenic functions of macrophage subsets | Q29620351 | ||
| Multi-SNP analysis of GWAS data identifies pathways associated with nonalcoholic fatty liver disease | Q30000787 | ||
| Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase | Q30032295 | ||
| Lipotoxicity in the liver. | Q30355131 | ||
| Kuppfer Cells Trigger Nonalcoholic Steatohepatitis Development in Diet-induced Mouse Model through Tumor Necrosis Factor-α Production | Q30416248 | ||
| Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis | Q30448524 | ||
| Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease | Q30464215 | ||
| Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis | Q30479092 | ||
| Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes | Q30496725 | ||
| Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey | Q30589720 | ||
| Alcohol consumption and the prevalence of the Metabolic Syndrome in the US.: a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey | Q30977059 | ||
| The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population | Q33262505 | ||
| Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease | Q33263279 | ||
| Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase | Q42563412 | ||
| M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease | Q42710363 | ||
| Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease | Q42727112 | ||
| Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis | Q42791977 | ||
| A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. | Q42836677 | ||
| Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. | Q42923153 | ||
| High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial | Q42947254 | ||
| Maternal obesity during pregnancy and lactation programs the development of offspring non-alcoholic fatty liver disease in mice | Q43088513 | ||
| Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. | Q43107476 | ||
| Protective role of coffee in non-alcoholic fatty liver disease (NAFLD). | Q43158194 | ||
| Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity | Q43200840 | ||
| Effects of coffee on inflammatory cytokine gene expression in mice fed high-fat diets | Q43245741 | ||
| Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup | Q43264433 | ||
| Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial | Q43265559 | ||
| Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis | Q43292661 | ||
| Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities | Q43552270 | ||
| Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study | Q43581539 | ||
| Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery | Q43637450 | ||
| Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese | Q43662697 | ||
| Insulin inhibits the maturation phase of VLDL assembly via a phosphoinositide 3-kinase-mediated event | Q43764610 | ||
| Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes | Q43833528 | ||
| Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease | Q43879331 | ||
| Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients | Q43984736 | ||
| Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. | Q44030028 | ||
| Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up | Q44116748 | ||
| Gender difference in hepatic steatosis index and lipid accumulation product ability to predict incident metabolic syndrome in the historical cohort of the Brisighella Heart Study | Q44214138 | ||
| Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis | Q44226725 | ||
| The global NAFLD epidemic | Q44238213 | ||
| The association of fatty liver and diabetes risk | Q44315967 | ||
| Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study | Q44381028 | ||
| Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis | Q44385942 | ||
| Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome | Q44385945 | ||
| Liver Stiffness Measurements in Patients with Different Stages of Nonalcoholic Fatty Liver Disease: Diagnostic Performance and Clinicopathological Correlation | Q44403442 | ||
| Long-term follow-up of patients with nonalcoholic fatty liver | Q44431564 | ||
| Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program | Q44437100 | ||
| Tumor necrosis factor-alpha directly stimulates the overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic insulin signaling | Q44463863 | ||
| The prevalence and etiology of elevated aminotransferase levels in the United States | Q44480010 | ||
| Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. | Q44527604 | ||
| Influence of Coffee Brew in Metabolic Syndrome and Type 2 Diabetes | Q44836012 | ||
| Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis | Q44849407 | ||
| Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. | Q45034517 | ||
| Light-to-moderate alcohol consumption and mortality in the Physicians' Health Study enrollment cohort | Q45038841 | ||
| Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis | Q45070082 | ||
| Prevalence of nonalcoholic fatty liver disease in coastal eastern India: a preliminary ultrasonographic survey. | Q45095608 | ||
| Alcohol consumption and metabolic syndrome: does the type of beverage matter? | Q45106107 | ||
| Value of Acoustic Radiation Force Impulse Imaging Elastography for Non-invasive Evaluation of Patients with Nonalcoholic Fatty Liver Disease | Q45127401 | ||
| Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients | Q45244529 | ||
| Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial | Q45417227 | ||
| Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population. | Q45955992 | ||
| High rates of fructose malabsorption are associated with reduced liver fat in obese African Americans. | Q45958757 | ||
| Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people | Q51395389 | ||
| Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States | Q51442516 | ||
| High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis | Q51453492 | ||
| Prevalence of non-alcoholic fatty liver disease: population based study. | Q51464103 | ||
| Effects of nonalcoholic fatty liver disease on the development of metabolic disorders | Q51468305 | ||
| Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD | Q51488901 | ||
| Effects of resistance or aerobic exercises on metabolic parameters in obese women who are not on a diet | Q51492223 | ||
| Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study | Q51497896 | ||
| Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study | Q51500156 | ||
| Dietary fat content modifies liver fat in overweight nondiabetic subjects | Q51521170 | ||
| Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity | Q51529134 | ||
| Effects of aerobic or resistance exercise and/or diet on glucose tolerance and plasma insulin levels in obese men. | Q51563449 | ||
| Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression. | Q51610482 | ||
| Alcohol consumption appears to protect against non-alcoholic fatty liver disease | Q51629368 | ||
| Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis | Q51665999 | ||
| Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease | Q51707737 | ||
| Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease | Q51757427 | ||
| Heritability and genetic loci of fatty liver in familial combined hyperlipidemia | Q51786382 | ||
| Serum markers detect the presence of liver fibrosis: a cohort study | Q51983072 | ||
| Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis | Q53555710 | ||
| Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients | Q53575022 | ||
| Polymorphism in the farnesyl diphosphate farnesyl transferase 1 gene and nonalcoholic fatty liver disease severity. | Q54381048 | ||
| Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people. | Q54427076 | ||
| Monocyte chemoattractant protein-1 (MCP-1) deficiency enhances alternatively activated M2 macrophages and ameliorates insulin resistance and fatty liver in lipoatrophic diabetic A-ZIP transgenic mice | Q54483243 | ||
| Reliability of transient elastography for the detection of fibrosis in Non-Alcoholic Fatty Liver Disease and chronic viral hepatitis | Q54513263 | ||
| Are statins 'IDEAL' for non-alcoholic fatty liver disease? | Q54758023 | ||
| Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis | Q34560068 | ||
| Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study | Q34583419 | ||
| A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis | Q34585893 | ||
| Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies | Q34589543 | ||
| The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis | Q34617479 | ||
| Susceptibility and gene interaction study of the angiotensin II type 1 receptor (AGTR1) gene polymorphisms with non-alcoholic fatty liver disease in a multi-ethnic population | Q34618881 | ||
| Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction | Q34627317 | ||
| Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. | Q34628009 | ||
| Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 | ||
| Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis | Q34713484 | ||
| Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes | Q34758501 | ||
| PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease | Q34759018 | ||
| Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease | Q34775679 | ||
| Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis. | Q34876724 | ||
| Interaction of physical trainings and coffee intakes in fuel utilization during exercise in rats | Q36920385 | ||
| Adipokines Mediate Inflammation and Insulin Resistance | Q36920864 | ||
| Racial differences in nonalcoholic fatty liver disease in the U.S. population | Q36948248 | ||
| Inverse Correlation Between Coffee Consumption and Prevalence of Metabolic Syndrome: Baseline Survey of the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study in Tokushima, Japan | Q36978708 | ||
| Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach | Q37039886 | ||
| Recent Advances in Obesity-Induced Inflammation and Insulin Resistance | Q37080182 | ||
| Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). | Q37127287 | ||
| Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis | Q37139481 | ||
| Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients | Q37141885 | ||
| Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction | Q37179529 | ||
| Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent | Q37197345 | ||
| Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis | Q37229854 | ||
| Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease | Q37248725 | ||
| A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). | Q37278117 | ||
| Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). | Q37286751 | ||
| Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? | Q37314124 | ||
| Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis | Q37318430 | ||
| A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. | Q37337449 | ||
| Genetic Variation at NCAN Locus Is Associated with Inflammation and Fibrosis in Non-Alcoholic Fatty Liver Disease in Morbid Obesity | Q37394350 | ||
| Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia | Q37397018 | ||
| Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene | Q37400771 | ||
| Curcumin attenuates the effects of insulin on stimulating hepatic stellate cell activation by interrupting insulin signaling and attenuating oxidative stress | Q37456073 | ||
| Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal | Q37578517 | ||
| Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease | Q37596730 | ||
| Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. | Q37638200 | ||
| Next-generation sequence analysis of genes associated with obesity and nonalcoholic fatty liver disease-related cirrhosis in extreme obesity | Q37693953 | ||
| Pathophysiology of NASH: Perspectives for a Targeted Treatment | Q37699476 | ||
| Roles of liver innate immune cells in nonalcoholic fatty liver disease | Q37793003 | ||
| Cell death and nonalcoholic steatohepatitis: where is ballooning relevant? | Q37863134 | ||
| The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. | Q37894169 | ||
| Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. | Q37896939 | ||
| Association of tumor necrosis factor‐α gene promoter polymorphism at sites ‐308 and ‐238 with non‐alcoholic fatty liver disease: A meta‐analysis | Q37957955 | ||
| The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease | Q37963122 | ||
| Crosstalk and barriers between the electron carriers of the endoplasmic reticulum. | Q37964777 | ||
| Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials | Q37978785 | ||
| Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis | Q82677113 | ||
| Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression | Q82727385 | ||
| A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis | Q82824308 | ||
| Coffee and Caffeine Improve Insulin Sensitivity and Glucose Tolerance in C57BL/6J Mice Fed a High-Fat Diet | Q82833188 | ||
| A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease | Q83186458 | ||
| Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis | Q83363620 | ||
| Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma | Q83462628 | ||
| Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality | Q83500394 | ||
| Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis | Q83978119 | ||
| Detection of non-alcoholic steatohepatitis in patients with morbid obesity before bariatric surgery: preliminary evaluation with acoustic radiation force impulse imaging | Q84250608 | ||
| Tumor necrosis factor--alpha gene promoter polymorphisms in Chinese patients with nonalcoholic fatty liver diseases | Q84305308 | ||
| Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years | Q84484058 | ||
| Association of Coffee and Caffeine Consumption With Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Degree of Hepatic Fibrosis | Q85072332 | ||
| Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial) | Q86416747 | ||
| Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH | Q86506810 | ||
| Efficacy of probucol for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label pilot study | Q86637098 | ||
| Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial | Q86674169 | ||
| Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography | Q86755842 | ||
| Predictive value of ALT levels for NASH and advanced fibrosis | Q87165740 | ||
| Peri-conceptional obesogenic exposure induces sex-specific programming of disease susceptibilities in adult mouse offspring. | Q45970847 | ||
| Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). | Q46012959 | ||
| Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. | Q46012961 | ||
| Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. | Q46021856 | ||
| Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. | Q46085888 | ||
| Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. | Q46117666 | ||
| A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans | Q46118770 | ||
| Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. | Q46124754 | ||
| Long-term maternal high-fat feeding from weaning through pregnancy and lactation predisposes offspring to hypertension, raised plasma lipids and fatty liver in mice. | Q46128368 | ||
| A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis | Q46177222 | ||
| Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease | Q46179069 | ||
| High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease | Q46202529 | ||
| Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol | Q46213176 | ||
| Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial | Q46216843 | ||
| Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia | Q46243154 | ||
| Comparison of blood tests for liver fibrosis specific or not to NAFLD. | Q46269528 | ||
| Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet | Q46306589 | ||
| Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis | Q46418008 | ||
| Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake | Q46473255 | ||
| Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people | Q46531274 | ||
| Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. | Q46533800 | ||
| Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. | Q46581129 | ||
| Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study | Q46680959 | ||
| Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease | Q46685325 | ||
| The effects of 24 weeks of moderate- or high-intensity exercise on insulin resistance | Q46694182 | ||
| A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease | Q46763155 | ||
| Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort | Q46793872 | ||
| High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. | Q46796856 | ||
| Caffeine is protective in patients with non‐alcoholic fatty liver disease | Q46818665 | ||
| Fatty liver and the metabolic syndrome among Shanghai adults | Q46841528 | ||
| The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients | Q46846844 | ||
| Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population | Q46856167 | ||
| Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). | Q46857868 | ||
| Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease | Q46920588 | ||
| Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial | Q47234529 | ||
| Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease | Q48588687 | ||
| Altered Phenotype and Functionality of Circulating Immune Cells Characterize Adult Patients with Nonalcoholic Steatohepatitis | Q50615299 | ||
| Maternal western diet primes non-alcoholic fatty liver disease in adult mouse offspring | Q50709798 | ||
| Habitual coffee but not green tea consumption is inversely associated with metabolic syndrome: an epidemiological study in a general Japanese population | Q50710032 | ||
| Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors | Q50781857 | ||
| Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene | Q50878523 | ||
| High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. | Q50953093 | ||
| Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia | Q51101920 | ||
| Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. | Q51171810 | ||
| Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease | Q51330295 | ||
| Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma | Q51347740 | ||
| Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients | Q51353878 | ||
| Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease | Q51364415 | ||
| Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis | Q51368607 | ||
| Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease | Q51394440 | ||
| Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis | Q33563333 | ||
| Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis | Q33568261 | ||
| Endpoints and clinical trial design for nonalcoholic steatohepatitis | Q33583798 | ||
| Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study | Q33596744 | ||
| Electron transport chain-dependent and -independent mechanisms of mitochondrial H2O2 emission during long-chain fatty acid oxidation | Q33648511 | ||
| Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis | Q33771703 | ||
| Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease | Q33777486 | ||
| Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis | Q33788174 | ||
| Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits | Q33851563 | ||
| Elevated endotoxin levels in non-alcoholic fatty liver disease | Q33864406 | ||
| Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease | Q33909796 | ||
| The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease | Q33937046 | ||
| Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity | Q33976477 | ||
| Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia | Q33987896 | ||
| Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. | Q34007373 | ||
| Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease | Q34069352 | ||
| The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease | Q34101263 | ||
| Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis | Q34116386 | ||
| Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography | Q34119521 | ||
| Saturated fatty acid induction of endoplasmic reticulum stress and apoptosis in human liver cells via the PERK/ATF4/CHOP signaling pathway | Q34128069 | ||
| A simple index of lipid overaccumulation is a good marker of liver steatosis | Q34134206 | ||
| Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells | Q34152594 | ||
| Liver and muscle in morbid obesity: the interplay of fatty liver and insulin resistance. | Q34168368 | ||
| Nonalcoholic steatohepatitis: definition and pathology | Q34215155 | ||
| Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials | Q34281575 | ||
| Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review | Q34304174 | ||
| Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes | Q34370610 | ||
| NAFLD, NASH and liver cancer | Q34374372 | ||
| Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. | Q34403314 | ||
| The spectrum of liver disease in the general population: lesson from the Dionysos study. | Q34420591 | ||
| Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease | Q34427653 | ||
| Genetic variant I148M in PNPLA3 is associated with the ultrasonography-determined steatosis degree in a Chinese population | Q34487178 | ||
| Genetic variants in PNPLA3 and risk of non-alcoholic fatty liver disease in a Han Chinese population | Q34505214 | ||
| Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. | Q34511187 | ||
| Taurine prevents arsenic-induced cardiac oxidative stress and apoptotic damage: role of NF-kappa B, p38 and JNK MAPK pathway | Q34992898 | ||
| An apoptosis panel for nonalcoholic steatohepatitis diagnosis | Q34995562 | ||
| Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome | Q35004042 | ||
| Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials | Q35024182 | ||
| Genetic polymorphisms in non-alcoholic fatty liver disease in obese Egyptian children | Q35098370 | ||
| Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. | Q35215184 | ||
| Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial | Q35490295 | ||
| Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice | Q35535851 | ||
| Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: the Rancho Bernardo Study | Q35563896 | ||
| Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life | Q35596306 | ||
| Effect of alcohol consumption on diabetes mellitus: a systematic review | Q35646391 | ||
| Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial | Q35681885 | ||
| The ins and outs of mitochondrial dysfunction in NASH. | Q35821156 | ||
| NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. | Q35931190 | ||
| A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease | Q36028519 | ||
| CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status | Q36047622 | ||
| Heritability of nonalcoholic fatty liver disease | Q36095663 | ||
| Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD) | Q36101050 | ||
| Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis | Q36168809 | ||
| Apoptosis in alcoholic and nonalcoholic steatohepatitis | Q36170407 | ||
| Benefits of lifestyle modification in NAFLD. | Q36172840 | ||
| Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice | Q36243894 | ||
| Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. | Q36297873 | ||
| Ceramides in insulin resistance and lipotoxicity | Q36381594 | ||
| Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease | Q36402141 | ||
| Hepatic histology in obese patients undergoing bariatric surgery | Q36561289 | ||
| NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease | Q36626940 | ||
| NAFLD fibrosis score: A prognostic predictor for mortality and liver complications among NAFLD patients | Q36654473 | ||
| Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States | Q36756206 | ||
| Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study | Q36764962 | ||
| Increased production of sonic hedgehog by ballooned hepatocytes | Q36773522 | ||
| Signals from dying hepatocytes trigger growth of liver progenitors | Q36785147 | ||
| The ERLIN1-CHUK-CWF19L1 gene cluster influences liver fat deposition and hepatic inflammation in the NHLBI Family Heart Study | Q36807854 | ||
| Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial | Q36886508 | ||
| Inflammasomes in liver diseases | Q38013465 | ||
| PNPLA3, a genetic marker of progressive liver disease, still hiding its metabolic function? | Q38033845 | ||
| Sterile Inflammation in the Liver | Q38043897 | ||
| Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. | Q38062786 | ||
| NAFLD in Asia--as common and important as in the West | Q38086356 | ||
| Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis | Q38090905 | ||
| Interaction of hepatic stellate cells with diverse types of immune cells: foe or friend? | Q38121575 | ||
| Lipokines and oxysterols: novel adipose-derived lipid hormones linking adipose dysfunction and insulin resistance | Q38129655 | ||
| Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments | Q38168939 | ||
| Hepatic accumulation of Hedgehog-reactive progenitors increases with severity of fatty liver damage in mice | Q38297119 | ||
| Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis | Q38310080 | ||
| Manganese superoxide dismutase is reduced in the liver of male but not female humans and rodents with non-alcoholic fatty liver disease | Q38311635 | ||
| Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver | Q38326652 | ||
| Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. | Q38356462 | ||
| Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. | Q38447369 | ||
| DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery | Q38487123 | ||
| Coffee polyphenols suppress diet-induced body fat accumulation by downregulating SREBP-1c and related molecules in C57BL/6J mice | Q39644781 | ||
| Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population | Q39693472 | ||
| Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. | Q39829317 | ||
| Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study | Q39880419 | ||
| Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease | Q39892915 | ||
| Non-alcoholic fatty liver disease and the metabolic syndrome in an urban hospital serving an African community | Q39979781 | ||
| Role for hedgehog signaling in hepatic stellate cell activation and viability | Q40371810 | ||
| Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity | Q40379756 | ||
| A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. | Q40464366 | ||
| Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice | Q40612270 | ||
| Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study | Q40942211 | ||
| A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease | Q42236490 | ||
| Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity | Q42409618 | ||
| Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). | Q42410021 | ||
| Maternal high-fat feeding through pregnancy and lactation predisposes mouse offspring to molecular insulin resistance and fatty liver | Q42487641 | ||
| Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. | Q55033443 | ||
| Diet-heart: a problematic revisit. | Q55052567 | ||
| Alcohol consumption and mortality among women. | Q55064753 | ||
| Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects | Q56981583 | ||
| Cognitive-behavioral treatment of nonalcoholic Fatty liver disease: a propensity score-adjusted observational study | Q56986303 | ||
| Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis | Q57205163 | ||
| Alcohol and Breast Cancer in Women | Q57268454 | ||
| Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis | Q57760188 | ||
| Hepatocyte Apoptosis, Expression of Death Receptors, and Activation of NF-κB in the Liver of Nonalcoholic and Alcoholic Steatohepatitis Patients | Q57760193 | ||
| How different is the dietary pattern in non-alcoholic steatohepatitis patients? | Q58058712 | ||
| Magnetic resonance imaging and spectroscopy for monitoring liver steatosis | Q59854628 | ||
| Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes | Q60265137 | ||
| Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease | Q60462153 | ||
| Gut microbiota and nonalcoholic fatty liver disease | Q61338001 | ||
| A position statement on NAFLD/NASH based on the EASL 2009 special conference | Q61338101 | ||
| The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD | Q61989968 | ||
| The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies | Q62607244 | ||
| Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis | Q63241959 | ||
| Overweight and obesity in the United States: prevalence and trends, 1960–1994 | Q64133342 | ||
| Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects | Q71655107 | ||
| Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds | Q73143340 | ||
| Sterol response element-binding protein 1c (SREBP1c) is involved in the polyunsaturated fatty acid suppression of hepatic S14 gene transcription | Q73157303 | ||
| Total and regional body composition across age in healthy Hispanic and white women of similar socioeconomic status | Q73315330 | ||
| Prevalence of and risk factors for hepatic steatosis in Northern Italy | Q73375973 | ||
| Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis | Q73735584 | ||
| Racial differences in visceral adipose tissue but not anthropometric markers of health-related variables | Q74113250 | ||
| Kupffer cell aggregation and perivenular distribution in steatohepatitis | Q74462552 | ||
| Gut-liver axis: a new point of attack to treat chronic liver damage? | Q74637262 | ||
| Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways | Q77807989 | ||
| One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation | Q78634574 | ||
| Oxidative-stress and IL-6 mediate the fibrogenic effects of [corrected] Kupffer cells on stellate cells | Q79390715 | ||
| Dietary habits and nutrient intake in non-alcoholic steatohepatitis | Q79399259 | ||
| Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis | Q79426743 | ||
| Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis | Q80064434 | ||
| Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease | Q80092840 | ||
| Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound | Q80341556 | ||
| Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis | Q80354878 | ||
| Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage | Q80387912 | ||
| The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis | Q80455381 | ||
| Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men | Q80709947 | ||
| Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis | Q81441036 | ||
| Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease | Q81926258 | ||
| Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial | Q82112174 | ||
| G308A polymorphism of TNF-alpha gene is associated with insulin resistance and histological changes in non alcoholic fatty liver disease patients | Q82347910 | ||
| Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease | Q82648058 | ||
| P433 | issue | 36 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver disease | Q929737 |
| metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
| fatty liver disease | Q6058862 | ||
| non-alcoholic fatty liver | Q66299798 | ||
| P304 | page(s) | 12956-12980 | |
| P577 | publication date | 2014-09-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Non-alcoholic fatty liver disease: what the clinician needs to know | |
| P478 | volume | 20 |
| Q36075087 | Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. |
| Q96127385 | Acot9 traffics mitochondrial short-chain fatty acids towards de novo lipogenesis and glucose production in the liver |
| Q91962512 | Acupuncture on ST36, CV4 and KI1 Suppresses the Progression of Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease in Mice |
| Q38721038 | Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis |
| Q91785566 | Association between NAFLD and Risk of Colorectal Adenoma in Chinese Han Population |
| Q30377409 | Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. |
| Q89699887 | Combined effect of n-3 fatty acids and phytosterol esters on alleviating hepatic steatosis in non-alcoholic fatty liver disease subjects: a double-blind placebo-controlled clinical trial |
| Q41125952 | Comparative study of fatty liver induced by methionine and choline-deficiency in C57BL/6N mice originating from three different sources |
| Q54760091 | Controlled Attenuation Parameter as a Noninvasive Method to Detect and Quantify Hepatic Steatosis in Chronic Liver Disease: What Is the Clinical Relevance? |
| Q90737605 | Dual-Specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through Transforming Growth Factor Beta-Activated Kinase 1 Suppression |
| Q92091142 | Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial |
| Q60921659 | Feasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies |
| Q28069174 | Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis |
| Q37146192 | Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review |
| Q26764913 | Glycosyltransferases and non-alcoholic fatty liver disease |
| Q64901221 | HNF1α Controls Liver Lipid Metabolism and Insulin Resistance via Negatively Regulating the SOCS-3-STAT3 Signaling Pathway. |
| Q89467581 | Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review |
| Q89273951 | Healthy dietary pattern is inversely associated with non-alcoholic fatty liver disease in elderly |
| Q55104113 | Heat shock protein 70 promotes lipogenesis in HepG2 cells. |
| Q92243745 | Hepatoprotective Effect of Jianpi Huoxue Formula on Nonalcoholic Fatty Liver Disease Induced by Methionine-Choline-Deficient Diet in Rat |
| Q45061974 | Human germline hedgehog pathway mutations predispose to fatty liver. |
| Q64071418 | Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes |
| Q49261126 | Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. |
| Q33643887 | Link Between Non-Alcoholic Fatty Liver Disease and Atrial Fibrillation: A Systematic Review and Meta-Analysis |
| Q36743546 | Low Serum Lysosomal Acid Lipase Activity Correlates with Advanced Liver Disease |
| Q54985271 | MiRNA-17 encoded by the miR-17-92 cluster increases the potential for steatosis in hepatoma cells by targeting CYP7A1. |
| Q52877979 | Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH). |
| Q89170081 | Monitoring liver damage using hepatocyte-specific methylation markers in cell-free circulating DNA |
| Q30375036 | Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. |
| Q35841934 | Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study). |
| Q64052598 | Non-alcoholic fatty liver disease and pregnancy complications among Sri Lankan women: A cross sectional analytical study |
| Q49830030 | Nonylphenol aggravates non-alcoholic fatty liver disease in high sucrose-high fat diet-treated rats |
| Q89864969 | Novel defatting strategies reduce lipid accumulation in primary human culture models of liver steatosis |
| Q26784396 | Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease |
| Q52882603 | Pathogenesis of Nonalcoholic Steatohepatitis |
| Q64087904 | Pathogenesis of and major animal models used for nonalcoholic fatty liver disease |
| Q90599861 | Prevalence and risk factors of sonographically detected non alcoholic fatty liver disease in a screening centre in Klang Valley, Malaysia: an observational cross-sectional study |
| Q28079534 | Prevalence of Non-alcoholic Fatty Liver Disease and Its Related Factors in Iran |
| Q90600274 | Puerarin Mitigates Diabetic Hepatic Steatosis and Fibrosis by Inhibiting TGF-β Signaling Pathway Activation in Type 2 Diabetic Rats |
| Q36009499 | Relationship of MTHFR gene 677C → T polymorphism, homocysteine, and estimated glomerular filtration rate levels with the risk of new-onset diabetes |
| Q51246325 | Risk factors and community intervention for nonalcoholic fatty liver disease in community residents of Urumqi, China |
| Q26743373 | Role of Hedgehog Signaling Pathway in NASH |
| Q58804681 | Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway |
| Q36550126 | Tetradecylthiopropionic acid induces hepatic mitochondrial dysfunction and steatosis, accompanied by increased plasma homocysteine in mice |
| Q36932993 | The Effect of Artichoke Leaf Extract on Alanine Aminotransferase and Aspartate Aminotransferase in the Patients with Nonalcoholic Steatohepatitis |
| Q52349162 | The hedgehog pathway in nonalcoholic fatty liver disease |
| Q46259732 | Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: a pilot trial. |
| Q52902850 | Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease |
| Q33638757 | Vitamin D3 supplementation of a high fat high sugar diet ameliorates prediabetic phenotype in female LDLR-/- and LDLR+/+ mice. |
Search more.